Division of Woman and Baby, Department of Gynaecological Oncology, University Medical Centre Utrecht, the Netherlands.
Int J Gynecol Cancer. 2012 Jan;22(1):170-4. doi: 10.1097/IGC.0b013e318226c636.
A recent study on the use of cancer antigen 125 (CA-125) in follow-up of patients with epithelial ovarian cancer after complete response on primary treatment is critically reviewed. As it has been suggested to refrain from CA-125 altogether, this European Society of Gynaecologic Oncology report has also reviewed possible disadvantages, even possible harm, and potentially missed opportunities when such policy would be implemented. It is concluded that indeed routine use of CA-125 does not provide patient benefit in survival or quality of life. However, there may be other reasons for monitoring CA-125, which are discussed in this review. It is noted that the lack of benefit of CA-125 monitoring has only been proven for a specific subset of ovarian cancer patients with serous histology and frequent follow-up visits including imaging and in a clinical environment where, particularly, surgery for recurrent disease and clinical studies on new second-line agents will not be considered. A special warning is issued not to stop tumor marker follow-up in other than epithelial ovarian cancers and in follow-up of patients who not have been treated with chemotherapy.
最近对原发性治疗完全缓解后上皮性卵巢癌患者随访中使用癌抗原 125（CA-125）的研究进行了批判性回顾。由于建议完全避免使用 CA-125，因此本欧洲妇科肿瘤学会报告还回顾了实施此类政策可能带来的潜在不利影响，甚至可能带来的危害和潜在错失的机会。结论是，CA-125 的常规使用实际上并不能提高患者的生存或生活质量。然而，监测 CA-125 可能还有其他原因，本综述对此进行了讨论。需要注意的是，CA-125 监测的益处仅在具有浆膜组织学和频繁随访（包括影像学检查）的特定卵巢癌亚组患者中得到证实，并且在特定临床环境下，例如，不会考虑针对复发性疾病的手术和新二线药物的临床研究。特别警告不要在非上皮性卵巢癌中以及未接受化疗的患者随访中停止肿瘤标志物随访。
